Philippines LOA Notarisation and Apostille: The Three-Step Chain

1. Key takeaways

Consular legalisation is no longer required. China acceded to the Convention Abolishing the Requirement of Legalisation for Foreign Public Documents on 8 March 2023, and the Convention entered into force between China and the Philippines on 7 November 2023. Since that date, public documents sent from China for use in the Philippines no longer go through consular legalisation and instead receive an Apostille. The complete chain is: manufacturer signs the LOA, a Chinese foreign-related notary office notarises it, and the Ministry of Foreign Affairs or an entrusted foreign affairs office issues the Apostille.

GRZAN note: the step that most companies get wrong is the middle one. An Apostille authenticates a public document, and a manufacturer-signed LOA is not one until a notary has converted it. The chain can be remembered as 3 steps replacing 5, with 1 mandatory notarisation in the middle and 1 online verification portal at the end.

• China acceded on 8 March 2023; the Convention took effect with the Philippines on 7 November 2023;
• No consular legalisation for public documents within the scope of the Convention;
• Notarisation of the LOA is a prerequisite to the Apostille;
• Apostilles are verifiable online.

The practical effect is a shortening of the critical path rather than a change in the legal test. The document still has to be authentic, and the authorisation it contains still has to be adequate; what has disappeared is the consular step that used to sit between notarisation and use.

2. Legal basis

The treaty basis, the dates, the issuing authorities and the verification route are summarised below. Two points in the table carry most of the operational weight: the identity of the competent authority, and the fact that a limited number of entrusted local offices can issue Apostilles for documents originating in their own administrative areas.

3. Expert insights

Insight 1: the Apostille applies to public documents, which is why notarisation is unavoidable. This is the point most often misunderstood. An Apostille certifies the authenticity of the signature on a public document, the capacity in which the signatory acted, and, where appropriate, the authenticity of the seal on the document. An LOA signed by the manufacturer is a private document and cannot be apostilled directly. It must first be notarised by a foreign-related notary office, converting the private document into a notarial certificate, and the Apostille is then issued for that certificate. If the order is reversed, the document cannot be processed at all.

Insight 2: compared with traditional consular legalisation, the chain shrinks from five steps to three. The old flow ran: signature, notarisation, authentication by the Ministry of Foreign Affairs, and legalisation by the Philippine Embassy or consulates in China — four to five steps in total, subject to consular district rules, prescribed forms and binding specifications. The new flow is signature, foreign-related notarisation, Apostille: three steps. This removes the single most time-consuming stage, the consular one, and is the most substantive facilitation for Chinese manufacturers entering the Philippine market since 2023.

Insight 3: Apostilles can be verified online, which changes how the FDA and customers check documents. Apostilles support online verification through the consular portal. For the marketing authorisation holder and for the FDA this means document authenticity can be confirmed electronically, reducing reliance on paper-based authentication. It is good practice to supply the verification reference together with the submission so that the reviewer can confirm the document quickly rather than setting it aside.

Insight 4: the content of the LOA matters more than the form of its authentication. Authentication answers whether the document is genuine; content answers whether the authorisation is sufficient. Four items should always be stated explicitly: the scope of authorisation, including the product list and the powers granted; the term of authorisation; the ownership of the registration data; and the duty to cooperate on termination. The fourth is what makes a future transfer possible. Once the holder changes or the authorisation expires, without that clause the outgoing holder has no obligation to cooperate.

4. Practical recommendations

• Keep the order fixed: foreign-related notarisation first, Apostille second. A private document presented directly for an Apostille will be refused.
• Start 4 to 6 weeks ahead. Third-party scheduling is outside the company’s own control, and the LOA itself carries a validity requirement.
• Draft all four LOA elements. Scope, term, ownership of registration data and the cooperation duty on termination.
• Handle the CFS notarisation and Apostille at the same time. Running both together saves a full cycle.
• Retain the online verification details. They let reviewers and customers confirm authenticity without correspondence.

The underlying logic is that authentication and content are separate workstreams that happen to converge in one document. Companies that plan them together usually finish both before the dossier is ready; companies that plan only the authentication often discover, at the point of transfer or renewal, that the authorisation they obtained was narrower than the business they built on it.

5. Verification checklist

• □ Convention applicability confirmed: in force between China and the Philippines from 7 November 2023
• □ Foreign-related notarisation completed, with the original notarial certificate on hand
• □ Apostille issued by the Ministry of Foreign Affairs or one of the 31 entrusted local offices
• □ Apostille verifiable online at consular.mfa.gov.cn/VERIFY/
• □ All four LOA elements present: scope, term, data ownership, cooperation on termination
• □ Validity not expired, checked against the issue date

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including the Philippines. Our team prepares CMDN/CMDR dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the FDA Philippines, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com